Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in advanced malignant pleural mesothelioma
NCT00128102Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2005
- Primary completion
- Jul 2011
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
01
Overview
A Phase 3 trial of vorinostat in malignant pleural mesothelioma (MPM), sponsored by Merck & Co.. Started Jun 2005; status: completed.
02
Drugs
vorinostat
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT00128102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00128102.